{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/delirium/prescribing-information/levomepromazine/","result":{"pageContext":{"chapter":{"id":"c02516c6-89cb-5dc3-99db-17f261f5f80e","slug":"levomepromazine","fullItemName":"Levomepromazine","depth":2,"htmlHeader":"<!-- begin field 12c6f407-a311-48e9-be18-e40abe030171 --><h2>Levomepromazine</h2><!-- end field 12c6f407-a311-48e9-be18-e40abe030171 -->","summary":"","htmlStringContent":"<!-- begin item 6f9b5e3f-0777-479b-8f4c-1b870aceeddc --><!-- begin field 4d0813ba-f988-4161-9234-1f5fc91471c4 --><ul><li>Levomepromazine is a first-generation antipsychotic drug which acts predominantly by blocking dopamine type 2 (D<sub>2</sub>) receptors in the brain. It is usually used as a second- or third-line anti-emetic because of its sedative effect.</li></ul><!-- end field 4d0813ba-f988-4161-9234-1f5fc91471c4 --><!-- end item 6f9b5e3f-0777-479b-8f4c-1b870aceeddc -->","topic":{"id":"6b89f111-d1d1-510e-8846-71e15c389f06","topicId":"64430de8-33e7-409d-b433-725a712a6f41","topicName":"Delirium","slug":"delirium","lastRevised":"Last revised in April 2020","chapters":[{"id":"0455d257-6ef6-5e50-9dc0-21780666b8e7","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a71db69b-5a97-544a-a806-ec82704f3907","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"58e84228-4844-5721-859b-91d58faa7eb6","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"999affe9-788e-52a9-83c8-ad933103eeb5","slug":"changes","fullItemName":"Changes"},{"id":"29c67640-566b-5fa4-8966-5b08ca667756","slug":"update","fullItemName":"Update"}]},{"id":"6dddaa0e-c24c-5f4e-8044-6a3229f859df","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"7e8bf385-fd9a-544a-bc9d-375555c17ab0","slug":"goals","fullItemName":"Goals"},{"id":"8f18311c-4fad-5969-8a94-addcca05fb64","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b45b0c3d-03c0-5300-b0c4-62ccd106e229","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7b7d4906-4705-52ba-a39f-ecfb7c5d1e98","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"331ceb18-88fc-530e-aa48-bae28dde9901","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"558ba6d3-06ab-5370-b6b7-09548f2c3c8e","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"b6e24e45-958a-5052-800a-ef5c6f140719","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"2b925b35-d493-5d01-bb58-9f18c37e1357","slug":"definition","fullItemName":"Definition"},{"id":"27bd26a5-66e1-5d51-a992-7e06e6a3cdfa","slug":"predisposing-factors","fullItemName":"Predisposing factors"},{"id":"c3582ffa-e505-5580-a3fa-f6a04f0938cc","slug":"precipitating-factors","fullItemName":"Precipitating factors"},{"id":"44402d85-ef9c-562b-ad2c-e99c0d8c60a7","slug":"prevalence","fullItemName":"Prevalence"},{"id":"799dcaa5-4683-5bf0-a9d7-dfc860ab7c81","slug":"complications","fullItemName":"Complications"},{"id":"ca4b25bd-2486-55a7-92c0-c39322caa272","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"993580f3-4201-5dd5-8a6d-f64de509d328","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"3f7d0746-b45f-5f52-8e49-7effac5e3547","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"f84af6b7-85fc-56aa-9554-29d1231a7fd1","slug":"assessment","fullItemName":"Assessment"},{"id":"cc3618cd-d41e-5719-939a-78ed0be305e4","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"9d04a09f-9612-570d-aeb7-c0121bda09c4","fullItemName":"Management","slug":"management","subChapters":[{"id":"81f2aa66-ed46-54f0-80b5-4dfca4afb344","slug":"management","fullItemName":"Scenario: Management"},{"id":"58bb812f-7b3c-57be-aab1-8ae228aff1d1","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"769a3265-9e21-5508-b937-bf6aa4a8f378","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"fa09afb1-cc68-5f68-afbe-7486c91a5ed4","slug":"haloperidol","fullItemName":"Haloperidol"},{"id":"4faac93d-8b62-5294-933f-214a1155f283","slug":"lorazepam","fullItemName":"Lorazepam"},{"id":"c02516c6-89cb-5dc3-99db-17f261f5f80e","slug":"levomepromazine","fullItemName":"Levomepromazine"}]},{"id":"cd438911-3d3a-51dd-8455-3e41c260dd60","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"cec2028c-5183-50fb-9bb7-f20aea64a152","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a5323429-af72-5d8b-a251-0715c1a15bba","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"26c6273a-60c7-5b9a-b49f-9f9fbb623941","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b70aed75-14ce-57f4-b2b0-474fa4480d56","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"c5faba8c-4118-59d9-af20-8c8d52a89eb2","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"71e02a81-885f-515f-8852-109bc9b5580f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"51d66a08-1fc6-5593-8764-c9d4e547d827","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"769a3265-9e21-5508-b937-bf6aa4a8f378","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"5334aadc-e835-5eb2-9d78-ce7f0d5185ee","slug":"dosage","fullItemName":"Dosage","depth":3,"htmlHeader":"<!-- begin field 03d349d2-7146-44aa-bae0-7dc1f474f9e1 --><h3>What dose of levomepromazine should I prescribe?</h3><!-- end field 03d349d2-7146-44aa-bae0-7dc1f474f9e1 -->","summary":"","htmlStringContent":"<!-- begin item 615699e1-5e7b-4e2b-bae5-d592716a2053 --><!-- begin field 0e89b3a7-d592-4682-bafc-57a18f979c91 --><ul><li>Levomepromazine may be given orally but is generally given by the subcutaneous route. It is usually given once a day, but some people may benefit from divided daily doses (twice or three times a day), or from continuous subcutaneous infusion.</li></ul><h4>Oral dosing</h4><ul><li>Levomepromazine 6 mg tablets are an unlicensed preparation and are available on a named-patient basis only.</li><li>They can be ordered directly from the manufacturer (but this can take up to 48 hours), or they may be available through the local palliative care team or hospice.</li><li>If the 6 mg tablets are not available, experts suggest using a quarter of a 25 mg tablet (that is 6.25 mg).</li></ul><h4>Subcutaneous dosing</h4><ul><li>When converting from the oral route to the subcutaneous route, the oral dose should be divided by two to get the equivalent subcutaneous dose.</li><li>A dose of 6.25 to 12.5mg may be administered subcutaneously (SC) 12 hourly.</li><li>If symptoms are controlled continue SC either as stat doses 12-24 hourly, or via syringe driver. </li><li>If symptoms are not controlled, increase the dose according to the level of patient distress and the response.</li><li>An initial<em> </em><strong>subcutaneous infusion dose </strong>of 12.5–50 mg/24 hours should be administered, titrated according to response. Doses greater than 100 mg/24 hours should only be given under specialist supervision.</li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/delirium/references/\">BNF 71, 2016</a>]</p><!-- end field 0e89b3a7-d592-4682-bafc-57a18f979c91 --><!-- end item 615699e1-5e7b-4e2b-bae5-d592716a2053 -->","subChapters":[]},{"id":"d1bdcae1-0b34-549a-b564-0f7d6f664e9d","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field d8d121a7-e242-4f7d-bec5-0080ac47bbfe --><h3>What are the adverse effects of levomepromazine?</h3><!-- end field d8d121a7-e242-4f7d-bec5-0080ac47bbfe -->","summary":"","htmlStringContent":"<!-- begin item 23dcf18f-19c9-4364-a539-a91739919fb7 --><!-- begin field 8e656120-5d74-4148-8196-ded1c1915318 --><ul><li>Adverse effects of levomepromazine include sedation (particularly at doses of 25 mg or more in 24 hours), dose-dependent postural hypotension, and antimuscarinic adverse effects (dry mouth, sedation, and blurred vision). Doses less than 12.5 mg daily do not usually cause problems.</li></ul><!-- end field 8e656120-5d74-4148-8196-ded1c1915318 --><!-- end item 23dcf18f-19c9-4364-a539-a91739919fb7 -->","subChapters":[]},{"id":"65b64903-b796-50c8-94ee-b453cc6d14ea","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 89c4c4e3-5cd9-48f1-867d-28e8da1d744a --><h3>What are the contraindications and cautions with levomepromazine?</h3><!-- end field 89c4c4e3-5cd9-48f1-867d-28e8da1d744a -->","summary":"","htmlStringContent":"<!-- begin item 5d33b734-d4bc-40e1-9ea6-0ac819e093de --><!-- begin field 6b7c6682-8bca-419e-9170-7e9d3ccb295f --><ul><li>Levomepromazine should be used with <strong>caution</strong> in patients with<ul><li>Cardiovascular disease (an ECG may be required, if physical examination identifies cardiovascular risk factors or if there is a personal history of cardiovascular disease).</li><li>Parkinson's disease (may be exacerbated by antipsychotics).</li><li>Epilepsy (and conditions predisposing to seizures).</li><li>Depression.</li><li>Myasthenia gravis.</li><li>Prostatic hypertrophy.</li><li>Susceptibility to angle-closure glaucoma.</li><li>Severe respiratory disease.</li><li>Patients with a history of jaundice.</li><li>Blood dyscrasias (perform blood counts if unexplained infection or fever develops).</li></ul></li><li>As photosensitisation may occur with higher dosages, patients should avoid direct sunlight [<a class=\"bibliography-reference internal-reference\" href=\"/topics/delirium/references/\">BNF 71, 2016</a>].</li><li>Levomepromazine may be <strong>contraindicated</strong> in comatose states, CNS depression and phaeochromocytoma. </li></ul><h4>Prescribing for the elderly </h4><ul><li>The balance of risks and benefit should be considered before prescribing antipsychotic drugs for elderly patients. In elderly patients with dementia, antipsychotic drugs are associated with a small increased risk of mortality and an increased risk of stroke or transient ischaemic attack. Furthermore, elderly patients are particularly susceptible to postural hypotension and to hyper- and hypothermia in hot or cold weather.</li><li>It is recommended that:<ul><li>Antipsychotic drugs should not be used in elderly patients to treat mild to moderate psychotic symptoms.</li><li>Initial doses of antipsychotic drugs in elderly patients should be reduced (to half the adult dose or less), taking into account factors such as the patient's weight, co-morbidity, and concomitant medication</li><li>Treatment should be reviewed regularly [<a class=\"bibliography-reference internal-reference\" href=\"/topics/delirium/references/\">BNF 71, 2016</a>].</li></ul></li><li>Clinical judgement should be exercised to balance the risks and benefits of prescribing levomepromazine to treat delirium in the end of life setting.</li></ul><!-- end field 6b7c6682-8bca-419e-9170-7e9d3ccb295f --><!-- end item 5d33b734-d4bc-40e1-9ea6-0ac819e093de -->","subChapters":[]},{"id":"9cb9b527-b10c-5603-9bf8-625224ea3f8d","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field fb50f615-3ef7-4ace-b677-63a732f72273 --><h3>What drug interactions can occur with levomepromazine?</h3><!-- end field fb50f615-3ef7-4ace-b677-63a732f72273 -->","summary":"","htmlStringContent":"<!-- begin item 67c11a28-7561-4490-b922-cdf478f47baf --><!-- begin field 0c085225-f356-4196-a99a-5664b6b34366 --><ul><li><strong>Cytochrome P450 2D6 Metabolism</strong>: Levomepromazine and its non-hydroxylated metabolites are reported to be potent inhibitors of cytochrome P450 2D6. Co-administration of levomepromazine and drugs primarily metabolised by the cytochrome P450 2D6 enzyme system (such as amiodarone, cimetidine, ciprofloxacin, fluoxetine, carbamazepine, warfarin, simvastatin) may result in increased plasma concentrations of the drugs that could increase or prolong either therapeutic or adverse effects of those drugs.</li><li><strong>Drugs which prolong the QT interval: </strong>There is an increased risk of arrhythmias when neuroleptics are used with drugs that prolong the QT interval such as certain class 1A and III antiarrhythmics (such as quinidine, disopyramide, procainamide, and amiodarone), certain antimicrobials (such as sparfloxacin, moxifloxacin and erythromycin IV), tricyclic antidepressants (e.g. amitriptyline), tetracyclic antidepressants (e.g. maprotiline), other neuroleptics (e.g. phenothiazines, pimozide and sertindole), antihistamines (e.g. terfenadine), cisapride, bretylium and antimalarials (e.g. quinine and mefloquine).</li><li><strong>Anticholingeric drugs:</strong> The anticholinergic effect of neuroleptics may be enhanced by other anticholinergic drugs.</li><li><strong>Diuretics:</strong> Avoid concomitant neuroleptics and any other drugs that may cause electrolyte imbalance. Diuretics, in particular those causing hypokalaemia, should be avoided but, if necessary, potassium-sparing diuretics are preferred.</li><li><strong>Desferrioxamine:</strong> Simultaneous administration of desferrioxamine and prochlorperazine has been observed to induce a transient metabolic encephalopathy, characterised by loss of consciousness for 48 to 72 hours. It is possible that this may occur with levomepromazine since it shares many of the pharmacological activities of prochlorperazine.</li><li><strong>Adrenaline:</strong> Adrenaline must not be used in patients overdosed with neuroleptics.</li><li><strong>Alcohol:</strong> Alcohol should be avoided. </li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/delirium/references/\">ABPI, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/delirium/references/\">BNF 71, 2016</a>]</p><!-- end field 0c085225-f356-4196-a99a-5664b6b34366 --><!-- end item 67c11a28-7561-4490-b922-cdf478f47baf -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}